Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: Comparison to the reversible binding P2Y 12 antagonist ticagrelor

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1179-1188

  Kuijpers, Marijke J E ^a   Megens, Remco T A ^b   Nikookhesal, Elham ^c   Feijge, Marion A H ^a   de Mey, J G R ^a   oude Egbrink, Mirjam G A ^a   van Giezen, J J J ^c   Heemskerk, Johan W M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

ADP receptors; Arterial thrombosis; Pharmacodynamics; Platelet physiology

Indexed keywords

CLOPIDOGREL; FIBRINOGEN; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; FLOW CYTOMETRY; IMAGE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SHEAR FLOW; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOGENESIS;

ADENOSINE; ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PLATELETS; CYTOPROTECTION; PLATELET ACTIVATION; PROTEIN BINDING; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RATS, INBRED WKY; THROMBOSIS; TICLOPIDINE;

EID: 82555193845     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-04-0252     Document Type: Article

References (34)

1. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304.
2. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 174-183.
3. Gurbel PA, Tantry US. Drug insight: Clopidogrel non-responsiveness. Nat Clin Pract Cardiovasc Med 2006; 3: 387-395.
4. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
5. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-STelevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-1208.
6. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
7. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
8. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
9. 12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-2012.
10. 12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006; 17: 250-258.
11. Mylotte D, Peace AJ, Tedesco AT, et al. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 2011; 9: 24-32.
12. Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a "rebound"phenomenon? Thromb Haemost 2011; 105: 211-220.
13. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009; 7: 1556-1565.
14. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
15. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
16. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
17. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
18. Van Giezen JJ. Optimizing platelet inhibition. Eur Heart J 2008; 10: D23-29.
19. Heemskerk JW, Kuijpers MJ, Munnix IC, et al. Platelet collagen receptors and coagulation. A characteristic platelet response as possible target for antithrombotic treatment. Trends Cardiovasc Med 2005; 15: 86-92.
20. Munnix IC, Strehl A, Kuijpers MJ, et al. The glycoprotein VI-phospholipase Cγ2 signaling pathway controls collagen- and tissue factor-induced thrombus formation in vitro and in vivo. Atheroscler Thromb Vasc Biol 2005; 25: 2673-2678.
21. Sigfridsson K, Björkman JA, Skantze P, et al. Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound. J Pharm Sci 2011; 100: 2194-2202.
22. 12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009; 124: 565-571.
23. 12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487-496.
24. Bannerman R. The mouse in biomedical research. New York 1983; Academic Press.
25. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
26. 12 and P2Y1 antagonists but not aspirin. Thromb Res 2005; 115: 301-307.
27. Kuijpers MJ, Gilio K, Reitsma S, et al. Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. J Thromb Haemost 2009; 7: 152-161.
28. Lecut C, Schoolmeester A, Kuijpers MJ, et al. Principal role of glycoprotein VI in α2β1 and αIIbβ3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004; 24: 1727-1733.
29. 12 receptors in shear-dependent thrombus formation on ruptured plaques. Plos One 2010; 5: e10130.
30. Cosemans JM, van Kruchten R, Olieslagers S, et al. Potentiating role of Gas6 and TAM receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost 2010; 8: 1797-1808.
31. Brass L. Fifty (or more) ways to leave your platelets (in a thrombus). Arterioscler Thromb Vasc Biol 2004; 24: 989-991.
32. 12 receptor occupancy. Thromb Haemost 2009; 101: 116-122.
33. 12 receptor: no active metabolite, no party. Nat Rev Cardiol 2009; 6: 271-272.
34. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.